• MoonLake Immunotherapeutics recently reported a first-quarter 2026 net loss of US$69.71 million alongside a positive final pre-BLA meeting with the FDA aligning on submission plans and label strategy for sonelokimab in hidradenitis suppurativa.
• A key takeaway is the FDA’s confirmation that existing adult and adolescent trial data appear acceptable for a Biologics License Application, removing identified regulatory gaps and clarifying MoonLake’s US commercialization path for sonelokimab.
• We’ll now examine how this regulatory alignment on sonelokimab’s planned label in hidradenitis suppurativa shapes MoonLake’s broader investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 46 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is MoonLake Immunotherapeutics' Investment Narrative?

To own MoonLake, you really have to believe sonelokimab can convert its hidradenitis suppurativa data into an approved, commercially relevant product while the company manages a period of heavy losses and zero revenue. The latest FDA pre-BLA meeting meaningfully tidies up the near-term picture: key regulatory uncertainties around the HS label, adolescent inclusion and safety package now look addressed, which strengthens confidence in the 2026 BLA submission and keeps the 2026–2027 HS launch timeline intact. Near-term catalysts remain concentrated in clinical and regulatory events, particularly the upcoming 52-week VELA data and multiple Phase 3 readouts, with this week’s update reducing one major binary risk but not eliminating the usual FDA and execution questions. Against that, MoonLake’s growing cash burn, dependence on a single late-stage asset and the need to potentially lean on its sizeable debt facility are still front and centre for shareholders.

However, one key concentration risk here is easy to underestimate. The valuation report we've compiled suggests that MoonLake Immunotherapeutics' current price could be inflated.

Exploring Other Perspectives

With one Simply Wall St Community fair value estimate clustered near US$27.62, you are seeing a very tight view of upside while the investment case still hinges on successful sonelokimab approval and careful cash management, so it is worth comparing this with other investors’ assumptions.

Explore another fair value estimate on MoonLake Immunotherapeutics - why the stock might be worth as much as 52% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your MoonLake Immunotherapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free MoonLake Immunotherapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MoonLake Immunotherapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.